Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancers.

Lung cancer is the first cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is a type of cancer that accounts for 85% of lung cancer. Its major risk factor is smoking. In patients with metastases, the main treatments combine chemotherapy and immunotherapy. lmmunotherapy involves boosting the immune system in order to unmask cancer cells and destroy them. Inflammation is a negative factor for immunotherapy efficacy. Inflammation is identified by several components in blood (i.e.) inflammatory biomarkers which can be measured in blood tests. Our team has created the Lung Immune Prognostic Index (LIPI) based on inflammatory biomarkers levels at the introduction of immunotherapy. The objective of this research is to apply the LIPI on a large population of patients included in prospective trials and to assess the potential value in the treatment choice for patients with lung cancer